Navigation Links
Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Date:8/19/2007

SAN DIEGO, Aug. 7 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today reported financial results for the quarter ended June 30, 2007. Revenues for the second quarter of 2007 were $3.1 million, compared with revenues of $7.3 million for the second quarter of 2006. The net loss for the second quarter of 2007 was $8.2 million, or $0.21 per share, compared with a net loss of $3.2 million, or $0.11 per share, for the second quarter of 2006. The increase in net loss reflected a proactive reduction of contract manufacturing activity and higher spending for advancement of the company's independent development programs.

Based on anticipated activities for the remainder of 2007, including acceleration of the company's pandemic influenza vaccine program, the company is revising its projection to a full-year net loss of between $32 million and $37 million and a net cash burn for the full year, excluding equity investments, of $27 million to $32 million. Vical had cash and investments of $82 million at June 30, 2007.

Pandemic Influenza IND Allowed

-- Vical has received notification of Investigational New Drug (IND)

allowance for its Phase 1 trial of the company's

Vaxfectin(TM)-formulated pandemic influenza DNA vaccine, and now

expects to initiate the trial earlier than originally planned during

the second half of 2007.

Other Advances in Product Development Programs

-- The company's licensee, AnGes MG, Inc. (AnGes), reported positive

results following an interim efficacy evaluation in its Japanese Phase

3 angiogenesis trial of its gene-based Hepatocyte Growth Factor (HGF)

product candidate in patients with advanced peripheral arterial disease

(PAD). Based on the recommendation of an Independent Data Monitoring

Committee, AnGes ended the trial early and is preparing an application

for Japanese marketing approval.

-- Vical announced
'/>"/>

SOURCE Vical

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6

Related medicine technology :

1. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
2. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
3. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
4. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
7. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
8. Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years
9. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
10. Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... England , August 20, 2014 ... be Conducted in the US  KalVista Pharmaceuticals ... macular edema (DME), today announces that it has begun ... novel plasma kallikrein inhibitor, KVD001, for the treatment of ... Sun of the Beetham Eye Institute, Joslin Diabetes Center; ...
(Date:8/19/2014)... Md. , Aug. 19, 2014  Northwest Biotherapeutics ... company developing DCVax® personalized immune therapies for solid tumor ... offering announced last Thursday, August 14, 2014, has closed.  ... are convertible at $7.30 per share of common stock.  ... months, to purchase up to an additional 30% of ...
(Date:8/19/2014)... YORK , Aug. 19, 2014  As ... around the country, Bernstein Liebhard LLP notes that ... can choose between a number of options that ... dangerous surgical instrument. According to a report published ... th , these options include a mini-laparotomy and ...
Breaking Medicine Technology:KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 3As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 3
... 24 Children,s Mental Focus,Foundation (CMFF), a nonprofit ... that may be linked to children with autism ... currently working with,doctors that have patients afflicted with ... adults cope with behavioral problems,associated with mental disorders ...
... Marketers, who have the,primary responsibility for communicating the ... as top challenges for pharmaceutical,companies when communicating trial ... worry about competitors stealing your,thunder, but also worry ... According to a Best Practices, LLC benchmarking study, ...
Cached Medicine Technology:Children's Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD 2Children's Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD 3Clinical Trial Best Practices: Savvy Marketers Plan Ahead with Early Communication Strategies 2
(Date:8/20/2014)... (PRWEB) August 20, 2014 Doctors at the ... to wipe out mesothelioma in laboratory mice by injecting them ... just posted details of the study on its website. ... Scientists with Hong Kong University’s AIDS Institute of Microbiology created ... 1” or PD-1. By altering DNA, the vaccine is designed ...
(Date:8/20/2014)... City, New Jersey (PRWEB) August 20, 2014 ... in meeting the needs of an estimated tens of ... introduction of the new Bill A3525—a bill that would ... patients to grow their own cannabis—earlier this summer by ... horticultural training for medicinal quality marijuana is growing. , ...
(Date:8/20/2014)... August is Children’s Eye Health and Safety ... eye health and safety for their children and have ... that must be checked for, according to Sharon Kleyne, ... radio show, is pediatric dry eye. With computer use ... is becoming a very real concern to ophthalmologists. , ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Hope For ... Give Hope® Celebration to be hosted in Washington, DC ... Navy Club. This signature event honors the courage of ... of the fallen. Proceeds from the Got Heart, Give ... national nonprofit dedicated to restoring a sense of self, ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Building ... healthcare, Jvion successfully predicted stage iii and iv ... in some situations, approached 90%. A company spokesperson ... achieved in commercial or academic settings. The resulting ... all types of hospital-acquired conditions to help providers ...
Breaking Medicine News(10 mins):Health News:New Research Study Finds Vaccine Stops Mesothelioma in Lab Mice, According to Surviving Mesothelioma Website 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 3Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 2Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 3Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Washington, DC 2Health News:Jvion Achieves Benchmark Accuracy in Pressure Ulcer Prediction 2
... The findings might boost understanding of the disease generally, ... The adult children of people with the rarer, inherited ... new study to better understand the biology of the ... biological parent diagnosed with a known genetic mutation causing ...
... 28 /PRNewswire-Asia/ -- CCID Consulting, China,s leading,research, consulting and ... listed in Hong Kong (Hong Kong Stock Exchange:,HK08235), recently ... , In 2007, ... an increase,in health awareness, which in turn drove the ...
... MD, noted medical researcher and women,s health practitioner, has spoken out ... well as other oral bisphosphonates such as Boniva, Actonel, and Fosamax. ... ... Susan Lark, MD , noted medical researcher and women,s health ...
... Africa, Nov. 27 20 top international,and local companies ... Awards Banquet held tonight at the Michelangelo Hotel in ... and innovation,across a variety of sectors. , ... , The awards ...
... after its use was banned, statistics show that nearly 4,000 people in the ... , ... Manchester,UK (PRWEB) November 27, 2008 -- On 24th November 1999, the Government,s ... statistics show that nearly 4,000 people in the UK die each year from ...
... care nurses are considering quitting in the next year ... Melbourne study. , The study, conducted by the Centre ... and the Australian Nursing Federation finds Victoria,s registered nurses ... not committed to their workplace. , It cites excessive ...
Cached Medicine News:Health News:Study Recruiting From Alzheimer's-Prone Families 2Health News:CCID Consulting Discusses China's Medical Equipment Market 2Health News:CCID Consulting Discusses China's Medical Equipment Market 3Health News:CCID Consulting Discusses China's Medical Equipment Market 4Health News:CCID Consulting Discusses China's Medical Equipment Market 5Health News:Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast 2Health News:Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast 3Health News:Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast 4Health News:Frost & Sullivan Recognises Best-in-Class Innovators 2Health News:Frost & Sullivan Recognises Best-in-Class Innovators 3Health News:Nine Year Ban Fails to Eradicate Asbestos Related Diseases 2Health News:Nine Year Ban Fails to Eradicate Asbestos Related Diseases 3Health News:Aged care workers to leave industry en masse due to stress, warns University of Melbourne study 2
Inquire...
Inquire...
... Optimal for Subcellular Fractionation, ... x g (30,000 rpm) with ... from 0.25 up to 85 ... 2° C to 40° C ...
... Fractionation, Proteins and Viruses • ... with fixed-angle rotor • Spin ... 85 mL • Operating temperature ... C • Rotors certified by ...
Medicine Products: